Estrone Sulfuric Acid

Summary

Estrone Sulfuric Acid (CHEMBL494753) is an approved small molecule targeting SLCO1A2, SLCO1B1, and SLCO1C1.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Targets: 6 (SLCO1A2, SLCO1B1, SLCO1C1…)
• Chemistry: 350.4 Da · C18H22O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL494753
Name	Estrone Sulfuric Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3001028
ChEBI	CHEBI:17474
Molecular formula	C18H22O5S
Molecular weight	350.4
InChIKey	JKKFKPJIXZFSSB-CBZIJGRNSA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O

IUPAC name: [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate

ChEBI definition: A steroid sulfate that is the 3-sulfate of estrone.

Other ChEBI roles (chemical / environmental): human metabolite, mouse metabolite.

Also known as: Estrone sulphate, SID11112590, Estrone sulfate, ESTROGENES_CONJUGUES, ESTROPIPATE, ESTRONE SULFURIC ACID

Parent form; salt/anhydrous children: CHEMBL1200980, CHEMBL1546237, CHEMBL2106240

Patent coverage: 1,024 distinct patent families (3,380 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,356 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SLCO1A2	OATP1A2			0.2%	P46721
SLCO1B1	OATP1B1			0%	Q9Y6L6
SLCO1C1	OATP1C1			0.1%	Q9NYB5
SLCO2B1	OATP2B1			0%	O94956
SLCO3A1	OATP3A1			0%	Q9UIG8
SLCO4A1	OATP4A1			0.9%	Q96BD0

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Solute carrier organic anion transporter family member 1B1, ATP-binding cassette sub-family C member 4, Solute carrier organic anion transporter family member 1A1, Organic anion transporter 3, Solute carrier organic anion transporter family member 1C1, Multidrug resistance-associated protein 1, Cytochrome P450 2C9, Steryl-sulfatase, Solute carrier family 22 member 20.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLCO1B1	7.34	Ki	45.8	nM	CHEMBL_ACT_11002244
ABCC1	6.35	Ki	450	nM	CHEMBL_ACT_11002287
P46720	5.89	Ki	1300	nM	CHEMBL_ACT_11002323
STS	5.12	IC50	7600	nM	CHEMBL_ACT_1223298
STS	5.12	IC50	7600	nM	CHEMBL_ACT_651362
Q9R1U7	5.04	Ki	9100	nM	CHEMBL_ACT_11003311

Target pathways

Aggregated over 6 target gene(s): SLCO1A2, SLCO1B1, SLCO1C1, SLCO2B1, SLCO3A1, SLCO4A1.

Top Reactome pathways

19 total, by targets touching each:

Pathway	Targets	Genes
Organic anion transport by SLCO transporters	6	SLCO1A2, SLCO1B1, SLCO1C1, SLCO2B1, SLCO3A1, SLCO4A1
Transport of small molecules	5	SLCO1A2, SLCO1B1, SLCO1C1, SLCO2B1, SLCO4A1
Transport of vitamins, nucleosides, and related molecules	5	SLCO1A2, SLCO1B1, SLCO1C1, SLCO2B1, SLCO4A1
SLC-mediated transmembrane transport	5	SLCO1A2, SLCO1B1, SLCO1C1, SLCO2B1, SLCO4A1
Metabolism	2	SLCO1A2, SLCO1B1
Recycling of bile acids and salts	2	SLCO1A2, SLCO1B1
Heme degradation	2	SLCO1B1, SLCO2B1
Bile acid and bile salt metabolism	2	SLCO1A2, SLCO1B1
Metabolism of lipids	2	SLCO1A2, SLCO1B1
Metabolism of steroids	2	SLCO1A2, SLCO1B1
Drug ADME	2	SLCO1A2, SLCO1B1
Atorvastatin ADME	2	SLCO1B1, SLCO2B1
Disease	1	SLCO1B1
Metabolism of porphyrins	1	SLCO1B1
SLC transporter disorders	1	SLCO1B1
Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)	1	SLCO1B1
Disorders of transmembrane transporters	1	SLCO1B1
Aspirin ADME	1	SLCO2B1
Ciprofloxacin ADME	1	SLCO1A2

Dominant GO biological processes

GO term	Targets
monoatomic ion transport	6
sodium-independent organic anion transport	6
transmembrane transport	6
obsolete organic anion transport	5
bile acid and bile salt transport	4
prostaglandin transport	4
xenobiotic metabolic process	3
lipid transport	3
thyroid hormone transport	3
transport across blood-brain barrier	3
heme catabolic process	2
obsolete organic cation transport	1
positive regulation of thyroid hormone generation	1
phenylalanine transport	1
tryptophan transport	1

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 9 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

302 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
dinoprostone	PubChem	Approved	SLCO1A2, SLCO1C1, SLCO2B1, SLCO3A1, SLCO4A1
Methotrexate	PubChem	Approved	SLCO1A2, SLCO1B1, SLCO1C1, SLCO2B1, SLCO3A1
Digoxin	ChEMBL + PubChem	Phase 4 (approved)	SLCO1A2, SLCO1B1, SLCO1C1, SLCO2B1
Lovastatin	ChEMBL + PubChem	Phase 4 (approved)	SLCO1A2, SLCO1B1, SLCO2B1
Pravastatin	ChEMBL + PubChem	Phase 4 (approved)	SLCO1A2, SLCO1B1, SLCO2B1
RIFAMPIN	ChEMBL + PubChem	Phase 4 (approved)	SLCO1A2, SLCO1B1, SLCO2B1
RIFAMYCIN	ChEMBL + PubChem	Phase 4 (approved)	SLCO1A2, SLCO1B1, SLCO2B1
Ritonavir	ChEMBL + PubChem	Phase 4 (approved)	SLCO1A2, SLCO1B1, SLCO2B1
Verapamil	ChEMBL + PubChem	Phase 4 (approved)	SLCO1A2, SLCO1B1, SLCO2B1
Glycyrrhizin	ChEMBL + PubChem	Phase 2 (approved)	SLCO1A2, SLCO1B1, SLCO2B1
aminohippuric acid	PubChem	Approved	SLCO1B1, SLCO2B1, SLCO3A1
Dexamethasone	PubChem	Approved	SLCO1A2, SLCO1B1, SLCO2B1
Erythromycin	PubChem	Approved	SLCO1A2, SLCO1B1, SLCO2B1
Liothyronine	PubChem	Approved	SLCO1A2, SLCO1C1, SLCO4A1
Penicillin G	PubChem	Approved	SLCO2B1, SLCO3A1, SLCO4A1
ATAZANAVIR	ChEMBL + PubChem	Phase 4 (approved)	SLCO1B1, SLCO2B1
ATORVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	SLCO1B1, SLCO2B1
CLARITHROMYCIN	ChEMBL + PubChem	Phase 4 (approved)	SLCO1B1, SLCO2B1
CYCLOSPORINE	ChEMBL + PubChem	Phase 4 (approved)	SLCO1B1, SLCO2B1
ERLOTINIB	ChEMBL + PubChem	Phase 4 (approved)	SLCO1B1, SLCO2B1
GEMFIBROZIL	ChEMBL + PubChem	Phase 4 (approved)	SLCO1B1, SLCO2B1
GLYBURIDE	ChEMBL + PubChem	Phase 4 (approved)	SLCO1B1, SLCO2B1
INDOMETHACIN	ChEMBL + PubChem	Phase 4 (approved)	SLCO1B1, SLCO2B1
OLMESARTAN MEDOXOMIL	ChEMBL + PubChem	Phase 4 (approved)	SLCO1B1, SLCO2B1
PACLITAXEL	ChEMBL + PubChem	Phase 4 (approved)	SLCO1B1, SLCO2B1
SIMVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	SLCO1B1, SLCO2B1
TELMISARTAN	ChEMBL + PubChem	Phase 4 (approved)	SLCO1B1, SLCO2B1
VINBLASTINE	ChEMBL + PubChem	Phase 4 (approved)	SLCO1B1, SLCO2B1
VINCRISTINE	ChEMBL + PubChem	Phase 4 (approved)	SLCO1B1, SLCO2B1
ELTROMBOPAG	ChEMBL	Phase 4 (approved)	SLCO1B1, SLCO2B1
SULFASALAZINE	ChEMBL	Phase 4 (approved)	SLCO1B1, SLCO2B1
SILYBIN A	ChEMBL	Phase 3	SLCO1B1, SLCO2B1
GENISTEIN	ChEMBL + PubChem	Phase 2 (approved)	SLCO1B1, SLCO2B1
SILICRISTIN	ChEMBL	Phase 2	SLCO1B1, SLCO2B1
Acyclovir	PubChem	Approved	SLCO1B1, SLCO2B1
Allopurinol	PubChem	Approved	SLCO1B1, SLCO2B1
Amantadine	PubChem	Approved	SLCO1B1, SLCO2B1
Amitriptyline	PubChem	Approved	SLCO1B1, SLCO2B1
Atenolol	PubChem	Approved	SLCO1B1, SLCO2B1
chenodiol	PubChem	Approved	SLCO1A2, SLCO1B1
Cholic Acid	PubChem	Approved	SLCO1B1, SLCO2B1
Enalapril	PubChem	Approved	SLCO1A2, SLCO2B1
Ezetimibe	PubChem	Approved	SLCO1B1, SLCO2B1
Fexofenadine	PubChem	Approved	SLCO1A2, SLCO2B1
mesalamine	PubChem	Approved	SLCO1A2, SLCO2B1
Metformin	PubChem	Approved	SLCO1B1, SLCO2B1
Nelfinavir	PubChem	Approved	SLCO1A2, SLCO2B1
Phenytoin	PubChem	Approved	SLCO1B1, SLCO2B1
Quinidine	PubChem	Approved	SLCO1A2, SLCO2B1
Saquinavir	PubChem	Approved	SLCO1A2, SLCO2B1
Sildenafil	PubChem	Approved	SLCO1B1, SLCO2B1
theophylline	PubChem	Approved	SLCO1B1, SLCO2B1
Valacyclovir	PubChem	Approved	SLCO1B1, SLCO2B1
TANNIC ACID	ChEMBL + PubChem	Phase 4 (approved)	SLCO1B1
BETA CAROTENE	ChEMBL	Phase 4 (approved)	SLCO1B1
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	SLCO1B1
CARBENOXOLONE	ChEMBL	Phase 4 (approved)	SLCO1B1
DICLOXACILLIN	ChEMBL	Phase 4 (approved)	SLCO1B1
ERYTHROMYCIN ESTOLATE	ChEMBL	Phase 4 (approved)	SLCO1B1
ERYTHROMYCIN ETHYLSUCCINATE	ChEMBL	Phase 4 (approved)	SLCO1B1